# Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

> **NCT03547973** · PHASE2 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 827 (estimated)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Avelumab
- **DRUG:** Zimberelimab
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Domvanalimab
- **DRUG:** Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT03547973
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-13
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 827 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547973, "Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT03547973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*